drugset / Trial / NCT02145676

OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity

NCT02145676 ↗

Phase 3 Terminated 53 enrolled Allergan
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a safety and efficacy study of onabotulinumtoxinA in poststroke patients with upper limb spasticity.

Timeline

Start
2014-05
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 300 iu Intramuscular
Subject Botulinum toxin type A Protein / enzyme biologic 500 iu Intramuscular

Indications